Immatics N.V. closed at $6.36 on Nov 6, up 2.91%, within 2.9% of its 52-week closing low. Volume of 1.1M shares was 0.88× its 20-day average (close to normal).
Split-adjusted performance: -13.7% over one month, -44.1% over six months, -28.9% over one year.
Short interest was 3.7M shares at the Oct 15 settlement, up 1.5% from the prior report (3.3% of float, 3.7 days to cover).
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
What is IMTX's market cap?
$968.15M, based on the Nov 6 close of $6.36.
Does Immatics N.V. pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IMTX is sold short?
3.7M shares, 3.3% of float, as of Oct 15, 2026.
About Immatics N.V
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
